Pyoderma gangrenosum associated with ulcerative colitis: Response to infliximab;Pioderma gangrenoso asociado a colitis ulcerosa: Respuesta a infliximab

Revista Espanola de Enfermedades Digestivas

Volumn 96, Issue 6, 2004, Pages 420-424

  Lopez San Roman A ^a   Bermejo San José, Fernando ^a,b   Aldanondo, I ^a   Carrera, E ^a   Boixeda, D ^a   Munoz Zato E ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b NONE   (Spain)

Author keywords

Infliximab; Pyoderma gangrenosum; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID DERIVATIVE; INFLIXIMAB; MESALAZINE; PREDNISONE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG INFUSION; ENDOSCOPY; ERYTHROCYTE SEDIMENTATION RATE; HEALING; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; LEG ULCER; MALE; PYODERMA GANGRENOSUM; SKIN BIOPSY; SKIN NECROSIS; THORAX RADIOGRAPHY; TIBIA; ULCER HEALING; ULCERATIVE COLITIS;

EID: 4344657108     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082004000600008     Document Type: Article

References (26)

1. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23: 29-34.
2. Levine JB, Lukawski-Trubish D. Extraintestinal considerations in IBD. Gastroenterol Clin North Am 1995; 24: 633-46.
3. Grand RJ. Treatment of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 1998; 4: 72-3.
4. Obrador A, López San Romón A, Muñoz P, Fortún J, Gassull MA. Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab. Gastroenterol Hepatol 2003; 26: 29-33.
5. Apgar JT. Newer aspects of inflammatory bowel disease and its cutaneous manifestations: a selective review. Semin Dermatol 1991; 10: 138-47.
6. Callen JP. Pyoderma gangrenosum. Lancet 1998; 351: 581-5.
7. Valer P, Bermejo F, López San Román A, Carrera E, González R, García Plaza A. Extraintestinal manifestations of inflammatory bowel disease (abstract). Rev Esp Enferm Dig 2003; 95 (Supl I): 79.
8. Friedman S, Marion JF, Scheri E: Rubin PH, Present DH. Intravenous cyclosporin in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 2001; 7: 1-7.
9. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
10. Present DH, Rutgeerts P, Targan SR, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
11. Su C, Salzberg BA, Lewis JD, Deren J, Kornbluth A, Katzka DA, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002; 97: 2576-84.
12. Probert CSJ, Hearing SD, Schreiber S, Kühbacher T, Ghosh S, Arnott IDR, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52: 998-1002.
13. Bermejo F, López San Román A, Hinojosa J, Castro L, Jurado C, Gómez-Belda AB. Infliximab induces clinical, endoscopical and histological response in refractory ulcerative colitis. Rev Esp Enferm Dig 2004; 96: 94-102.
14. Botros N, Pickover L, Das KM. Image of the Month. Pyoderma gangrenosum caused by ulcerative colitis. Gastroenterology 2000; 118: 654.
15. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 2001; 137: 930-3.
16. Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther. 2001; 15: 1639-46.
17. Hong JJ, Merel NJ, Hanauer SB. Treatment of pyoderma gangrenosum complicating Crohn's disease with infliximab. Gastroenterology 2001; 120: A621.
18. Romero-Gómez M, Sánchez-Muñoz D. Infliximab induces remission of pyoderma gangrenosum. Eur J Gastroenterol Hepatol 2002; 14: 907.
19. Triantafillidis JK, Cheracakis P, Sklavaina M, Apostolopoulou K. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol 2002; 37: 863-5.
20. Ljung T, Staun M, Grove O, Fausa O, Vatn MH, Hellstrom PM. Pyoderma gangrenosum associated with Crohn's disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 2002; 37: 1108-10.
21. Grange F, Djilali-Bouzina F, Weiss AM, Polette A, Guillaume JC. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab. Dermatology 2002; 205: 278-80.
22. Batres LA, Mamula P, Baldassano RN. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn's disease. J Pediatr Gastroenterol Nutt 2002; 34: 558-60.
23. Zaccagna A, Bertone A, Puiatti P, Picciotto F, Sprujevnik T, Santucci R, et al. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease. Eur J Dermatol 2003; 13: 258-60.
24. Mimouni D, Anhalt GJ, Kouba DJ, Nousari HC. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 2003; 148: 813-6.
25. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1821-6.
26. Domènech E, Esteve-Comas M, Gomollón F, Hinojosa J, Obrador A, Panés J, et al. Recommendations for the use of infliximab (Remicade®) in Crohn's disease. GETECCU 2001. Gastroenterol Hepatol 2002; 25: 162-9.